We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+58.52%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$34.9M
Cap. Flow
+$21.4M
Cap. Flow %
18.75%
Top 10 Hldgs %
76.05%
Holding
48
New
9
Increased
7
Reduced
9
Closed
20

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$9.39M
2
GPCR icon
Structure Therapeutics
GPCR
+$8.78M
3
ZLAB icon
Zai Lab
ZLAB
+$7.78M
4
NVCR icon
NovoCure
NVCR
+$5.91M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.61M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$5.02M
2
KROS icon
Keros Therapeutics
KROS
+$3.39M
3
ACLX
Arcellx
ACLX
+$3.26M
4
ARWR icon
Arrowhead Research
ARWR
+$2.89M
5
ONC
BeOne Medicines Ltd
ONC
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
26
Cullinan Oncology
CGEM
$1.01B
$349K 0.31%
+20,840
New +$370K
LSB
27
DELISTED
LakeShore Biopharma
LSB
$212K 0.19%
30,792
– –
CLYM
28
Climb Bio
CLYM
$720M
$172K 0.15%
+33,824
New +$239K
ACLX
29
DELISTED
Arcellx
ACLX
– –
-59,133
Closed -$3.26M
ALLK
30
DELISTED
Allakos
ALLK
– –
-940,578
Closed -$941K
APGE icon
31
Apogee Therapeutics
APGE
$10.1B
– –
-36,928
Closed -$1.45M
ARWR icon
32
Arrowhead Research
ARWR
$10.1B
– –
-111,133
Closed -$2.89M
CATX icon
33
Perspective Therapeutics
CATX
$336M
– –
-87,638
Closed -$874K
CMPS
34
Compass Pathways
CMPS
$1.68B
– –
-32,497
Closed -$196K
CTMX icon
35
CytomX Therapeutics
CTMX
$798M
– –
-1,151,518
Closed -$1.4M
EYPT icon
36
EyePoint Inc
EYPT
$1.09B
– –
-37,838
Closed -$329K
KPTI icon
37
Karyopharm Therapeutics
KPTI
$213M
– –
-35,632
Closed -$464K
KROS icon
38
Keros Therapeutics
KROS
$210M
– –
-74,288
Closed -$3.39M
KURA icon
39
Kura Oncology
KURA
$967M
– –
-36,242
Closed -$746K
MRSN
40
DELISTED
Mersana Therapeutics
MRSN
– –
-4,403
Closed -$221K
NAMS icon
41
NewAmsterdam Pharma
NAMS
$3.63B
– –
-64,213
Closed -$1.23M
PEPG icon
42
PepGen
PEPG
$156M
– –
-29,249
Closed -$467K
PYXS icon
43
Pyxis Oncology
PYXS
$141M
– –
-484,443
Closed -$1.6M
ATYR
44
aTyr Pharma
ATYR
$50.6M
– –
-313,028
Closed -$488K
ONC
45
BeOne Medicines Ltd
ONC
$32.9B
– –
-12,508
Closed -$1.78M
SPRB
46
Spruce Biosciences
SPRB
$122M
– –
-1,040
Closed -$40.4K
SYRS
47
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-37,789
Closed -$195K
MRNS
48
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-261,861
Closed -$306K
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Superstring Capital Management held 48 positions worth $114M, up 44% from $79.3M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Superstring Capital Management deployed $21.4M of net new capital in Q3 2024, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Oric Pharmaceuticals: 949,522 shares worth $9.73M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Legend Biotech, an estimated $5.02M trimmed.

  • Superstring Capital Management's largest Q3 2024 buy was Oric Pharmaceuticals: 949,522 shares worth $9.73M.
  • Superstring Capital Management added most to Zai Lab in Q3 2024, an estimated $7.78M increase.
  • Superstring Capital Management's biggest Q3 2024 reduction was Legend Biotech, cutting an estimated $5.02M.
  • Superstring Capital Management fully exited Keros Therapeutics in Q3 2024, selling an estimated $3.39M.
  • Superstring Capital Management's ten largest holdings make up 76% of its $114M portfolio in Q3 2024.
  • Superstring Capital Management opened 9 new positions and closed 20 in Q3 2024.
  • Superstring Capital Management's portfolio value rose 44% quarter-over-quarter to $114M.

Based on Superstring Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.